ÇAĞLAYAN ATEŞ

Dr. ÇAĞLAYAN ATEŞ

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2024 in Cirugía y Cirujanos
Verified
Journal Article
Open access
PDF file
ÇAÇAĞLAYAN ATEŞ
ÇAĞLAYAN ATEŞ
BDBerna Dilbaz
Berna Dilbaz
SESeval Yılmaz Ergani
Seval Yılmaz Ergani
FAFuad Atabay
Fuad Atabay
Objetivo: Mostrar por primera vez cómo afecta aflibercept a las lesiones de endometriosis. Material y métodos: Endometriosis inducida quir&uacu...

1 January 2023 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
ÇAÇAĞLAYAN ATEŞ
ÇAĞLAYAN ATEŞ
BDBerna Dilbaz
Berna Dilbaz
SESeval Yılmaz Ergani
Seval Yılmaz Ergani
FAFuad Atabay
Fuad Atabay
In this study, we aimed to determine the impact of the antiangiogenic medications, namely, aflibercept and cabergoline in the prevention and treatment of ovarian hyperstimulation syndrome in a rat model.

14 April 2026 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
ÇAÇAĞLAYAN ATEŞ
ÇAĞLAYAN ATEŞ
BDBerna Dilbaz
Berna Dilbaz
ETElif Göknur Topçu
Elif Göknur Topçu
SESelçuk Erkılınç
Selçuk Erkılınç

11 November 2025 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
ÇAÇAĞLAYAN ATEŞ
ÇAĞLAYAN ATEŞ
BDBerna Dilbaz
Berna Dilbaz
KSKoray Görkem Saçıntı
Koray Görkem Saçıntı

20 March 2026 in The European Journal of Contraception & Reproductive Health Care
Verified
Journal Article
Closed access
BDBerna Dilbaz
Berna Dilbaz
ÇAÇAĞLAYAN ATEŞ
ÇAĞLAYAN ATEŞ
This debate paper aims to examine the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), whose use in obesity and diabetes management has rapidly expanded, on fertility, contraceptive efficacy, and pregnancy outcomes in reproductive-aged individuals, and to provide evidence-based clinical guidance. GLP-1 RAs improve fertility in obese women with polycystic ovary syndrome (PCOS) through weight reduction and enhanced insulin sensitivity, meta-analyses demonstrated significantly higher spontaneous pregnancy rates. However, gastrointestinal side effects may theoretically compromise the absorption of oral contraceptives. Animal studies indicate potential foetal risks, and limited human data support discontinuation before conception with appropriate washout periods (2-4 weeks for short-acting agents, 8 weeks for semaglutide and tirzepatide). In men, metabolic improvements may indirectly enhance reproductive parameters. From a contraceptive perspective, non-oral hormonal methods and long-acting reversible contraception may represent more reliable options during treatment, particularly in the presence of gastrointestinal side effects that could compromise oral drug absorption. GLP-1 RAs are valuable adjuncts in managing obesity-related infertility, particularly in patients with PCOS. Clinicians must counsel patients regarding contraceptive reliability during treatment, ensure adequate washout before attempting conception, and recognise that while fertility benefits are well documented, pregnancy safety data remain limited.

5 August 2025 in Turkish Journal of Osteoporosis
Verified
Journal Article
Open access
PDF file
EYEthem Serdar Yalvaç
Ethem Serdar Yalvaç
ÇAÇAĞLAYAN ATEŞ
ÇAĞLAYAN ATEŞ
MBMUSTAFA BAKIRCI
MUSTAFA BAKIRCI
EŞEmine Yeşilyurt Şölen
Emine Yeşilyurt Şölen
FKFulya Kayıkçıoğlu
Fulya Kayıkçıoğlu
TOTaylan Onat
Taylan Onat
Composition of the vaginal microbiota in relation to cervical intraepithelial lesions - Turkish Journal of Obstetrics and Gynecology